A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF NL-201 IN PATIENTS WITH B-CELL LYMPHOMA, HODGKIN LYMPHOMA, OR MULTIPLE MYELOMA
- Registry ID
- NL201-103
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- NEOLEUKIN THERAPEUTICS INC.
- Last update
- 2022-03-03
Conditions
- HODGKIN LYMPHOMA
- MULTIPLE MYELOMA
- B-CELL NON-HODGKIN'S LYMPHOMA
Related clinical trials
- A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- PHASE I DOSE ESCALATION STUDY OF LIPOSOMAL CURCUMIN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
- A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL, GROUP-SEQUENTIAL,
PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF
INTRAVENOUS GAMMAGARD LIQUID (IMMUNE GLOBULIN INFUSION, 10%) FOR
PRIMARY INFECTION PROPHYLAXIS COMPARED WITH SECONDARY INFECTION
PROPHYLAXIS IN ADULT SUBJECTS WITH MULTIPLE MYELOMA RECEIVING B-CELL
MATURATION ANTIGEN×CD3¿DIRECTED BISPECIFIC ANTIBODY THERAPY
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY
AND SAFETY OF BMS-986393, A GPRC5D-DIRECTED CAR-T CELL THERAPY, VERSUS
STANDARD REGIMENS IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY AND
LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
View on source registry